Skip to main content
SpringerLink
Log in

Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Studies suggest infliximab decreases hospitalization and surgery rates in Crohn’fs disease (CD). The aim of this analysis was to evaluate adherence to infliximab maintenance therapy and the impact of medication adherence on health care utilization and costs by patients with CD.

Methods

Patients with CD who had at least four infliximab infusions (with the time between consecutive infusions ≤12 weeks for the first four infusions) during the first year following infliximab initiation (index date) were identified from the Integrated Health Care Information Service claims database (2002–2006). Nonadherence was defined as fewer than seven infliximab infusions in the first year. One-year health care resource utilization and costs (excluding infliximab drug and administration costs) were compared between adherent and nonadherent patients, with adjustment for baseline characteristics.

Results

A total of 571 patients with CD who were receiving infliximab maintenance therapy were identified. The infusion-based nonadherence rate was 34.3% during the first year of therapy. The multivariate analysis demonstrated that compared with adherent patients, nonadherent patients were more likely to have been hospitalized (odds ratio [OR]=2.7 [all-cause] and OR=2.5 [CD-related]; both P<0.001). Compared with infliximab-adherent patients, adjusted medical costs by nonadherent patients were 73% ($6,692) and 90% ($4,961) greater for all-cause and CD-related medical costs, respectively (both P<0.001), and adjusted hospitalization costs were 115% ($11,450) and 115% ($9,570) greater for all-cause and CD-related hospitalization costs, respectively (both P<0.001).

Conclusion

More than one-third of patients on infliximab maintenance therapy were nonadherent to recommended maintenance. Further, nonadherence was associated with increased medical costs and a greater rate of hospitalization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Loftus EV Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60.

    Article  PubMed  Google Scholar 

  2. Kamm MA. Review article: chronic active disease and maintaining remission in Crohn’s disease. Aliment Pharmacol Ther. 2004;20(suppl. 4):102–105.

    Article  CAS  PubMed  Google Scholar 

  3. Bebb JR, Scott BB. How effective are the usual treatments for Crohn’s disease? Aliment Pharmacol Ther. 2004;20:151–159.

    Article  CAS  PubMed  Google Scholar 

  4. US Food and Drug Administration. Center for Drug Evaluation and Research. Remicade® label and approval history. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed August 13, 2009.

  5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.

    Article  CAS  PubMed  Google Scholar 

  6. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff. 2001;20:64–78.

    Article  CAS  Google Scholar 

  7. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008;14 (1 suppl. A):s2–s12; quiz s13–s15.

    PubMed  Google Scholar 

  8. Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis. 2007;13:1244–1249.

    Article  PubMed  Google Scholar 

  9. Lopez San Roman A, Bermejo F, Carrera E, Perez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97:249–257.

    CAS  PubMed  Google Scholar 

  10. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27(suppl. 1):9–14.

    Article  PubMed  Google Scholar 

  11. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535–1544.

    Article  PubMed  Google Scholar 

  12. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25:1035–1043.

    Article  CAS  PubMed  Google Scholar 

  13. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust. 2006;185:487–489.

    PubMed  Google Scholar 

  14. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43.

    Article  PubMed  Google Scholar 

  15. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020–1024.

    Article  PubMed  Google Scholar 

  16. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179–1183.

    Article  CAS  PubMed  Google Scholar 

  17. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn’fs disease. Aliment Pharmacol Ther. 2007;26:217–225.

    Article  CAS  PubMed  Google Scholar 

  18. Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S, Raptis N, Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn’fs disease in long-term remission? Inflamm Bowel Dis. 2007;13:446–450.

    Article  PubMed  Google Scholar 

  19. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’fs disease. Aliment Pharmacol Ther. 2006;24:1099–1103.

    Article  CAS  PubMed  Google Scholar 

  20. Kane S, Wu EQ, Chen L, et al. Adherence to infliximab maintenance therapy and its impact on hospitalization of patients with Crohn’fs disease. Value Health. 2008;11:A88.A89.

    Google Scholar 

  21. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’fs disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–328.

    Article  CAS  PubMed  Google Scholar 

  22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.

    Article  CAS  PubMed  Google Scholar 

  23. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:2165–2169.

    Article  PubMed  Google Scholar 

  24. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’fs disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91–96.

    Article  PubMed  Google Scholar 

  25. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, 200 First Street SW, Rochester, Minnesota, 55905, USA

    Sunanda V. Kane

  2. Abbott Laboratories, Abbott Park, Illinois, Chicago, USA

    Jingdong Chao & Parvez M. Mulani

Authors
  1. Sunanda V. Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingdong Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parvez M. Mulani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunanda V. Kane.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kane, S.V., Chao, J. & Mulani, P.M. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Therapy 26, 936–946 (2009). https://doi.org/10.1007/s12325-009-0069-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0069-7

Keywords

Search

Navigation